Pancreatic cancer is a devastating disease. Previous research shows a correlation between a specific oncogene change (ras-mutation) and enhanced sensitivity to two chemotherapy drugs combined: gemcitabine and etoposide. This Phase II trial will evaluate this drug combination for locally advanced and metastatic pancreatic cancer.

Start Date01 Mar 2002

Sponsor / Collaborator

Spectrum Health Hospitals, Inc.

[+8]

100 Clinical Results associated with Metropolitan Hospital

0 Patents (Medical) associated with Metropolitan Hospital

539

Literatures (Medical) associated with Metropolitan Hospital

01 Dec 2025·Current Cardiology Reports

Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease

Review

Author: Katsiki, Niki ; Vrablik, Michal ; Kolovou, Genovefa

PURPOSE OF REVIEWIn recent years, the terms "metabolic associated fatty liver disease-MAFLD" and "metabolic dysfunction-associated steatotic liver disease-MASLD" were introduced to improve the encapsulation of metabolic dysregulation in this patient population, as well as to avoid the negative/stigmatizing terms "non-alcoholic" and "fatty".RECENT FINDINGSThere is evidence suggesting links between MASLD and coronary heart disease (CHD), heart failure (HF), atrial fibrillation (AF), stroke, peripheral artery disease (PAD) and chronic kidney disease (CKD), although the data for HF, AF, stroke and PAD are scarcer. Physicians should consider the associations between MASLD and CV diseases in their daily practice. Based on this knowledge and current guidelines, they should also assess and manage CV risk/co-morbidities in such patients. It is important to further investigate the impact of MASLD on CV outcomes, a knowledge that will help to elucidate the clinical implications of this "novel" liver entity.

21 Apr 2025·Cancer Research

Abstract 1992: Detection rate for ESR1 mutations is higher in CTC-derived genomic DNA than in paired plasma cfDNA samples as revealed by ddPCR

Author: Psyrri, Amanda ; Tserpeli, Victoria ; Smilkou, Stavroula ; Razis, Evangelia ; Papadimitriou, Christos ; Lianidou, Evi ; Ntzifa, Aliki ; Balgkouranidou, Ioanna ; Papatheodoridi, Alkistis ; Kakolyris, Stylianos ; Zagouri, Flora ; Linardou, Helena

AbstractPlasma cell-free DNA (cfDNA) analysis to track estrogen receptor 1 (ESR1) mutations is highly beneficial for the identification of tumor molecular dynamics and the improvement of personalized treatments for patients with metastatic breast cancer (MBC). Plasma cfDNA is, up to now, the most frequent liquid biopsy analyte used to evaluate ESR1 mutational status. Circulating tumor cell (CTC) enumeration and molecular characterization analysis provides important clinical information in patients with MBC. In this study, we investigated whether analysis of CTCs and circulating tumor DNA (ctDNA) provide similar or complementary information for the analysis of ESR1 mutations. We analyzed both plasma cfDNA (n=90) and paired CTC-derived genomic DNA (gDNA; n=42) from 90 MBC patients for seven ESR1 mutations. Eight out of 90 (8.9%) plasma cfDNA samples tested using the ddPLEX Mutation Detection Assay (Bio-Rad), were found positive for one ESR1 mutation, whereas 11/42 (26.2%) CTC-derived gDNA samples were found positive for at least one ESR1 mutation. Direct comparison of paired samples (n=42) revealed that the ESR1 mutation rate was higher in CTC-derived gDNA (11/42, 26.2%) than in plasma cfDNA (6/42, 14.3%) samples. Our results, using this highly sensitive ddPLEX assay, reveal a higher percentage of mutations in CTC-derived gDNAs than in paired ctDNA in patients with MBC. CTC-derived gDNA analysis should be further evaluated as an important and complementary tool to ctDNA for identifying patients with ESR1 mutations and for guiding individualized therapy.Citation Format:Stavroula Smilkou, Aliki Ntzifa, Victoria Tserpeli, Ioanna Balgkouranidou, Alkistis Papatheodoridi, Evangelia Razis, Helena Linardou, Christos Papadimitriou, Amanda Psyrri, Flora Zagouri, Stylianos Kakolyris, Evi Lianidou. Detection rate for ESR1 mutations is higher in CTC-derived genomic DNA than in paired plasma cfDNA samples as revealed by ddPCR [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1992.

01 Jan 2025·International Urogynecology Journal

Impact of Treatment of Pudendal Neuralgia on Pain: A Systematic Review and Meta-Analysis

Review

Author: Baruch, David ; Phillips, Dena ; Shatkin, Juliet E ; Toal, Catherine A ; Huang, Audrey ; Cohen, Michelle ; Mahmood, Sumaita ; Glass, Mikaela F ; Pollack, Bracha L ; Maron, Julia S ; Sacks, Ashley J ; Yaskhi, Gagana ; Sciarrino, Michelle ; Grimes, Cara L ; Cosgro, Ryan P ; Andiman, Sarah E ; Drugge, Elizabeth ; Spaulding, Gregory C ; Dandolu, Vani ; Vasey, MegAnne M ; Ricciardi, Francesca ; Loike-Weinstein, Devora

INTRODUCTION AND HYPOTHESISPudendal neuralgia is chronic pelvic pain associated with the pudendal nerve. Unfortunately, the best treatment approach is unknown. Our objective was to systematically assess interventions for pudendal neuralgia for improvement in pain.METHODSFollowing Preferred Reporting Items for Systematic Reviews and Meta-Analyses, we retrieved studies from MEDLINE, EMBASE, and clinicaltrials.gov through May 27, 2024. Our population included patients with pudendal neuralgia. Our interventions included surgery (decompression and nerve stimulation), injections and pulse radiofrequency treatments. Outcomes included improvement in pain (usually on a visual analog scale (VAS)) and adverse events. GRADE criteria were used to assess quality. Differences between pre- and post-intervention pain scores were compared with a random effects REML model and reported as mean difference and 95% confidence intervals.RESULTSSix hundred eighty-seven abstracts were screened yielding 37 studies that met eligibility criteria. Treatments included 16 surgeries with 12 nerve decompressions and 4 nerve stimulator placements, 14 injections, and 7 pulse radiofrequency treatments. The majority, 95%, were Grade C. All treatments appear to provide relief to a similar extent (mean difference in VAS of 2.73 cm (1.77, 3.69), p < 0.07, with high heterogeneity I² = 98.18%), but no treatment was clearly superior for pain relief. Adverse events were inconsistently reported but more severe in the surgery group.CONCLUSIONSThere are many treatment approaches to pudendal neuralgia, but overall, the evidence includes heterogeneous patient populations, non-standardized treatments, poor-quality studies, variable pain measurement instruments, and short-term follow-up. All interventions improved pain with no statistically significant difference between groups.

100 Deals associated with Metropolitan Hospital

100 Translational Medicine associated with Metropolitan Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 13 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

DC-rIL-2-VMO ( IL-2R )	Melanoma More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Metropolitan Hospital

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 13 May 2025

Current Projects

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing